[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Minia University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":604},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,75,0,25,[9,50,79,96,119,142,163,194,225,248,273,294,316,337,357,376,401,419,438,472,498,522,540,558,583],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100625855","postoperative-hypocalcemia-after-thyroidectomy-100625855",false,"NCT07428057","Postoperative Hypocalcemia After Thyroidectomy","A Ten-Year Cohort Study of Clinical and Surgical Predictors for Hypocalcemia Post-Thyroidectomy","Inclusion Criteria:\n\n* Adult patients aged 18 years or older at time of surgery\n* Underwent thyroidectomy at Minia University Hospital\n* Availability of medical records with complete surgical and postoperative data\n* Documented serum calcium levels measured postoperatively\n* Minimum follow-up of 6 months postoperatively or documented outcome status\n\nExclusion Criteria:\n\n* Age less than 18 years at time of surgery\n* Preoperative hypocalcemia (serum calcium \\\u003C8.0 mg\u002FdL or ionized calcium \\\u003C1.0 mmol\u002FL)\n* Pre-existing parathyroid disorders (primary hyperparathyroidism, hypoparathyroidism, secondary or tertiary hyperparathyroidism)\n* Chronic kidney disease Stage 3 or higher (estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Malabsorption syndromes affecting calcium metabolism (celiac disease, inflammatory bowel disease,short bowel syndrome)\n* Concurrent planned parathyroidectomy\n* History of neck irradiation\n* Chronic use of medications significantly affecting calcium metabolism (bisphosphonates, denosumab,cinacalcet, chronic corticosteroids)\n* Incomplete medical records lacking essential data including surgical details, postoperative calcium levels,or follow-up data\n* Patients lost to follow-up before 6-month endpoint without documented outcome status","ALL","18 Years","75 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","This retrospective cohort study investigates predictors of postoperative hypocalcemia following thyroidectomy procedures at Minia University Hospital over a 10-year period (2014-2024). Postthyroidectomy hypocalcemia is one of the most common complications of thyroid surgery, affecting 20-50% of patients. The study aims to identify demographic, clinical, laboratory, and surgical factors associated with the development of both transient and permanent hypocalcemia. Results will inform risk stratification, patient counseling, and perioperative management strategies.",[26,27,28,29,30],"Thyroid Nodule","Thyroid Dysfunction","Hypocalcemia","Thyroid Cancer","Postoperative Complications",[32,33,34,35,36],"Thyroidectomy","Postoperative hypocalcemia","Hypoparathyroidism","Parathyroid gland injury","Total thyroidectomy","RECRUITING","2026-06-27",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":41},"2026-03-04",{"date":45,"type":22},"2026-08-01",{"name":47,"class":48},"Minia University","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100594635","predictive-risk-factors-for-pancreatic-fistula-after-pancreaticoduodenectomy-100594635","NCT07022015","Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy","Predictive Risk Factors for Postoperative Pancreatic Fistula After Pancreaticoduodenectomy for Malignancy.","POPF","Inclusion Criteria:\n\n* Patients with resectable distal common bile duct carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas.\n* Patients meeting the curative treatment intent in accordance with clinical guidelines:\n\n  * No evidence of metastasis.\n  * Radiological non-involvement of superior mesenteric vein \\& portal vein.\n* American Society of Anesthesiologists (ASA) scores I \\& II.\n* Patients aged \\> 18 years.\n* Ability to understand and the willingness to sign a written informed consent document\n* Agreement to complete the study\n\nExclusion Criteria:\n\n* Unfit patients for surgery due to severe medical illness.\n* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.\n* Irresectable tumors in diagnostic laparoscopy.\n* History of other malignant disease.\n* Pregnant or breast-feeding women.\n* Patients with serious mental disorders.\n* Patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team according to abdominal imaging data.\n* Pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis\n* Patients refused to participate in the study.",{"count":59,"type":22},100,"INTERVENTIONAL",[62],"NA","Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD. In this study, the investigators aim to determine the predictive risk factors for clinically related postoperative pancreatic fistula (CR-POPF) in the preoperative, intraoperative and postoperative period in patients that underwent PD. The total number of 100 participants expected to be included in this research who underwent PD between 2025 and 2026.",[65,66,67,68,69,70,71],"Pancreas Cancer","Pancreas Neoplasm","Pancreatic Fistula","Pancreas Adenocarcinoma","Periampullary Cancer","Periampullary Carcinoma","Resectable Pancreatic Cancer",{"date":73,"type":41},"2026-07-01",{"date":75,"type":41},"2025-06-20",{"date":77,"type":22},"2026-10-20",{"name":47,"class":48},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":86,"targetDuration":4,"studyType":60,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":49},"100573225","external-pancreatic-stent-in-pancreaticojejunostomy-100573225","NCT06743516","External Pancreatic Stent in Pancreaticojejunostomy","The Impact of External Pancreatic Drainage During Pancreaticojejunostomy Following Pancreaticoduodenectomy in Cases of Soft Pancreas","Inclusion Criteria:\n\n* Patients undergoing pancreaticoduodenectomy (Whipple procedure) for various indications (e.g., pancreatic cancer, ampullary cancer, etc.).\n* Patients with a confirmed soft pancreas texture, as determined intraoperatively by the surgeon.\n\nExclusion Criteria:\n\n* Patients with a hard or fibrotic pancreas, as determined intraoperatively by the surgeon.\n* Patients with severe uncontrolled comorbidities (e.g., uncontrolled diabetes, severe cardiovascular disease, renal failure).\n* Pregnancy or lactation.",{"count":59,"type":22},[62],"Pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. To reduce pancreatic fistula, many authors recommend pancreatic stent in pancreatojejunostomy. The purpose of this study is to determine which is the best method in preventing pancreatic fistula and to investigate its long term clinical outcomes.",[67],{"date":40,"type":41},{"date":92,"type":41},"2025-01-01",{"date":94,"type":22},"2026-09-01",{"name":47,"class":48},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":17,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":60,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100631429","ultrasound-guided-infratemporal-sphenopalatine-ganglion-supravoltage-versus-standard-voltage-pulsed-radiofrequency-for-pain-alleviation-in-chronic-refractory-migraine-100631429","NCT07500558","Ultrasound Guided Infratemporal Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for Pain Alleviation in Chronic Refractory Migraine.","Ultrasound Guided Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for Pain Alleviation in Chronic Refractory Migraine. Randomized Double Blind Study","Inclusion Criteria:\n\n* Diagnosis of chronic migraine according to International Classification of Headache Disorders criteria (≥15 headache days\u002Fmonth for \\>3 months, including ≥8 migraine days\u002Fmonth) documented by Completion of 4-week prospective baseline headache diary immediately preceding randomization\n\n  * Failure of ≥2 classes of preventive pharmacological migraine medications (e.g., beta-blockers, antiepileptics, antidepressants...) to get clinically meaningful response ( defined as ≥50% reduction in monthly migraine days), at standard therapeutic doses (Beta-blockers (e.g., propranolol ≥160 mg\u002Fday, metoprolol ≥100 mg\u002Fday, Antiepileptics (e.g., topiramate ≥100 mg\u002Fday, valproate ≥500 mg\u002Fday, Tricyclic antidepressants (e.g., amitriptyline ≥50 mg\u002Fday, SNRIs (e.g., venlafaxine ≥150 mg\u002Fday ) for at least 8 weeks or ≥12 weeks in case of CGRP ).\n  * Stable preventive migraine therapy for at least 4 weeks prior to enrollment.\n  * MIDAS score ≥11 indicating moderate to severe disability.\n  * Ability and willingness to maintain a daily headache diary throughout the study period.\n  * Ability to provide written informed consent. Positive response (≥50% pain reduction within 30-60 minutes) to diagnostic INFRATEMPORAL sphenopalatine ganglion block using 2% lidocaine (2 mL) infrazygomatic approach\n\nExclusion Criteria:\n\n* Medication Overuse Headache per ICHD-3: Simple analgesics (acetaminophen, NSAIDs, non-opioid analgesics) used on ≥15 days per month for \\>3 months, OR Triptans, ergot derivatives, opioids, or combination analgesics used on ≥10 days per month for \\>3 months.\n* Any secondary headache disorder ( cluster headache, hemiplegic migraine, migraine with brainstem aura (distinct pathophysiology); chronic tension-type headache \\>10 days\u002Fmonth.\n* Any prior SPG block, PRF, radiofrequency thermocoagulation, chemical neurolysis, or neurostimulation of SPG\u002Ftrigeminal system within 6 month.\n* No prior occipital or supra-orbital nerve radiofrequency, cryotherapy, or chemical neurolysis within 3 months\n* Use of botulinum toxin (Botox) within 3 months or CGRP monoclonal antibodies within 3 months prior to enrollment.\n* Active psychosis, bipolar disorder (current manic\u002Fdepressive episode), severe depression with suicidal ideation, dementia, or substance use disorder (DSM-5 criteria) within 12 months; PHQ-9 ≥20 or cognitive impairment affecting reporting reliability.\n* Cardiac pacemaker, ICD, neurostimulator, or cochlear implant; or ECT.\n* Chronic uncontroled hypertension ; history of stroke, intracranial aneurysm, or high risk for cardiovascular events.\n* Pregnancy or lactation, Initiation, discontinuation, or modification of hormonal contraceptive therapy within 3 months prior to enrollment.\n\nCoagulopathy (platelets \\\u003C100,000 or INR \\>1.5) or ongoing anticoagulation not safely withheld.\n\n-Patient refusal.","20 Years","70 Years",{"count":59,"type":22},[62],"* PRF performed on the sphenopalatine ganglion level under ultrasound guidance.\n* Standard voltage PRF parameters: 45 V, 5 Hz frequency, 5 ms pulse width, 360 seconds duration, electrode temperature ≤42°C.\n* Supravoltage PRF parameters: Higher voltage than standard (e.g., 60-70 V), with same frequency, pulse width, and duration, maintaining temperature ≤42°C to avoid nerve damage.",[109],"Chronic Migraine, Headache","2026-06-13",{"date":112,"type":41},"2026-06-16",{"date":114,"type":41},"2026-03-31",{"date":116,"type":22},"2027-04-02",{"name":47,"class":48},2,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":125,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":60,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100639171","impact-of-vertical-vs-transverse-closure-on-outcomes-of-laparoscopic-correction-of-isthmocele-100639171","NCT07625852","Impact of Vertical vs. Transverse Closure on Outcomes of Laparoscopic Correction of Isthmocele","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Diagnosis of symptomatic isthmocele confirmed by transvaginal ultrasound (myometrial thickness at the defect \\\u003C 2.5 mm).\n* History of at least one prior cesarean section.\n* Symptoms attributable to isthmocele (e.g., abnormal uterine bleeding, pelvic pain, dysmenorrhea, secondary infertility).\n* Desire for surgical correction of isthmocele.\n* Ability to understand and provide informed consent\n\nExclusion Criteria:\n\n* Asymptomatic isthmocele.\n* Active pelvic infection or malignancy.\n* Significant medical comorbidities contraindicating laparoscopic surgery.\n* Coagulopathy.\n* Known uterine anomalies (e.g., bicornuate uterus).\n* Pregnancy at the time of recruitment.\n* Inability to comply with follow-up protocol.","FEMALE","45 Years",{"count":128,"type":22},72,[62],"Laparoscopic repair of Isthmocele aims to restore the anatomical integrity and physiological function of the lower uterine segment.\n\n* Vertical Closure: This technique involves closing the defect along the longitudinal axis of the uterus. Proponents suggest it may be more anatomically aligned with the muscle fibers of the lower uterine segment, potentially leading to stronger scar formation and reduced tension.\n* Transverse Closure: This technique involves closing the defect perpendicular to the long axis of the uterus. This approach is more commonly used during primary cesarean sections.\n\nArguments for transverse closure in isthmocele repair include familiarity for surgeons and potentially less shortening of the lower uterine segment.\n\nHowever, the actual impact of these different closure methods on long-term outcomes such as defect recurrence, scar integrity, and fertility, remains largely unexplored in a randomized controlled trial setting.",[132],"Isthmocele","NOT_YET_RECRUITING","2026-05-29",{"date":136,"type":41},"2026-06-04",{"date":138,"type":22},"2026-06-01",{"date":140,"type":22},"2027-06-01",{"name":47,"class":48},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":150,"targetDuration":4,"studyType":60,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":162,"locationsCount":49},"100638194","effect-of-silicon-oil-on-retinal-electrical-functions-using-multifocal-electroretinogram-100638194","NCT07609628","Effect of Silicon Oil on Retinal Electrical Functions Using Multifocal Electroretinogram","Effect of Silicon Oil on Retinal Electrical Functions in Patients With Rhegmatogenous Retinal Detatchment Using Multifocal Electroretinogram .","SO\u002FRRD\u002FmfERG","Inclusion Criteria:\n\n\\- Patients with primary rhegmatogenous retinal detachment\n\nExclusion Criteria:\n\n* Patients with history of previous intraocular surgery.\n* Patients with combined traction-rhegmatogenous retinal detachment\n* Patients with ocular disease as glaucoma ,degenerative myopia,age related macular degeneration\n* Patients with poor fixation.\n* Uncooperative patients.\n* Patients with retinopathy.\n* emulsified SO or complicated SO removal were excluded from this study",{"count":151,"type":22},50,[62],"Retinal detachment is one of the leading causes for permanent vision loss.Incidence of Rheugmatogenous Retinal Detachment (RRD) about 10.5 people per 100,000 population pars plana vitrectomy is the most popular and effective surgical options.\n\nTamponade agents as silicone oils are used to restore intraocular volume and apply surface tension to the detached retinal surface Silicone oil (SO) is a liquid containing polymerized siloxane with organic side chains. It has a high thermal stability, is hydrophobic, and chemically inert. The use of silicone oils as intraocular tamponades dates from 1962.",[155],"Rhegmatogenous Retinal Detachment","2026-05-21",{"date":158,"type":41},"2026-05-27",{"date":160,"type":41},"2026-02-01",{"date":45,"type":22},{"name":47,"class":48},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":174,"studyType":23,"phases":4,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":49},"100604066","anastomotic-leakage-after-colorectal-surgery-100604066","NCT07144683","Anastomotic Leakage After Colorectal Surgery.","Risk Factors for Anastomotic Leakage After Colorectal Surgery.","AL","Inclusion Criteria:\n\n* Aged ≥18 years\n* Undergoing elective or emergency colorectal resection with primary anastomosis (e.g., ileocolic, colocolic, colorectal, coloanal)\n* Providing written informed consent\n\nExclusion Criteria:\n\n* Colorectal resection without anastomosis (e.g., end stoma)\n* Inflammatory bowel disease (Crohn's, ulcerative colitis)\n* History of previous colorectal surgery involving anastomosis\n* Pregnancy\n* Unable to provide informed consent or comply with follow-up","80 Years",{"count":173,"type":22},430,"1 Year","Anastomotic leakage (AL) is a severe complication after colorectal surgery, with incidence rates of 2-30%. This prospective, single-center observational cohort study aims to identify and quantify independent risk factors for AL, determine its incidence and impact on outcomes, and develop a predictive model. Approximately 430 patients undergoing colorectal resection with anastomosis will be enrolled from August 2025 to August 2026. Risk factors will be assessed preoperatively, intraoperatively, and postoperatively. AL will be defined and graded per the International Study Group of Rectal Cancer (ISGRC) criteria.",[177,178,179],"Anastomotic Leak","Colorectal Cancer","Diverticulitis",[181,182,183,184,185],"Anastomotic leakage","Colorectal surgery","Risk factors","Postoperative complications","Predictive model","2026-05-17",{"date":188,"type":41},"2026-05-19",{"date":190,"type":41},"2025-08-25",{"date":192,"type":22},"2026-09-25",{"name":47,"class":48},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":60,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100637480","effect-of-a-herbal-intracanal-medication-on-postoperative-pain-and-flare-up-incidence-in-non-surgical-root-canal-retreatment-100637480","NCT07578311","Effect of a Herbal Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment","Effect Of Phytotherapeutics As Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment. (Randomized Clinical Trial)","Inclusion Criteria:\n\n* Failed previously performed endodontic treatment of single-rooted teeth.\n* Presence of a periapical lesion ranging from 1 mm to 2 mm in diameter.\n* Teeth with complete root formation.\n* Teeth without evidence of external or internal root resorption.\n\nExclusion Criteria:\n\n* Pregnant females.\n* Patients with uncontrolled systemic diseases.\n* Patients currently under antibiotic or analgesic administration.\n* Patients presenting with facial swelling.\n* Teeth not indicated for endodontic retreatment (e.g., poor oral hygiene, mobile teeth, or recessed teeth).",true,{"count":203,"type":22},40,[62],"The primary objective of this randomized clinical trial is to evaluate and compare the effectiveness of two natural, herbal-based intracanal medications-Propolis and Green Tea Polyphenolics (EGCG)-against the conventional Calcium Hydroxide in reducing postoperative pain and the incidence of flare-ups during non-surgical root canal retreatment.\n\nPostoperative pain is a common complication in endodontics, particularly in retreatment cases where complex bacterial environments and procedural challenges increase the risk of discomfort and acute flare-ups. While Calcium Hydroxide is the traditional gold standard due to its antimicrobial properties, natural phytotherapeutics like Propolis and Green Tea are being investigated for their potent anti-inflammatory, antioxidant, and antibacterial benefits, which may offer superior biocompatibility and symptomatic relief.\n\nForty patients requiring endodontic retreatment of single-rooted teeth will be randomly assigned to one of three groups:\n\nGroup I (Control): Receives Calcium Hydroxide paste.\n\nGroup II: Receives Propolis-based medication.\n\nGroup III: Receives Green Tea Polyphenolic-based medication.\n\nThe study follows a two-visit protocol. During the first visit, the previous root canal filling is removed, the canal is cleaned and shaped, and the assigned medication is placed. Postoperative pain will be assessed using a Visual Analog Scale (VAS) at 6, 12, 24, 48, 72 hours, and 7 days. Flare-up incidence (sudden severe pain or swelling) will also be monitored. In the second visit, the medication is removed, and the canal is permanently sealed using a bioceramic sealer and gutta-percha. The results will help determine if these herbal alternatives can provide a more comfortable treatment experience for patients undergoing root canal retreatment.",[207,208,209],"Postoperative Pain","Flare Up, Symptom","Flare up",[211,212,213,214,215,216],"postoperative pain","flare up","intra-canal medication","calcium hydroxide","propolis","Green Tea Polyphenolics","2026-05-05",{"date":219,"type":41},"2026-05-11",{"date":221,"type":22},"2026-07",{"date":223,"type":22},"2027-02",{"name":47,"class":48},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":232,"maxAge":19,"enrollmentInfo":233,"targetDuration":4,"studyType":60,"phases":235,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":49},"100573076","early-phase-1-pre-operative-intra-nasal-dexmedetomidine-or-insulin-for-prevention-of-early-post-operative-cognitive-dysfunction-in-patients-undergoing-elective-coronary-artery-bypass-graft-100573076","NCT06741566","Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.","Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft. A Comparative Randomized Bi-centric Study","Inclusion Criteria:\n\n* Adult population, 60 years or above, both sex, candidate for elective on pump coronary revascularization\n\nExclusion Criteria:\n\n* patient refusal\n* combined reperfusion and valve replacement operations.\n* Emergency or redo CABG.\n* preoperative MMSE score less than 20\n* preoperative cardiomyopathy (ejection fraction \\\u003C40%).\n* previous history of cerebrovascular stroke or carotid endarterectomy, dementia, language, hearing or visual impairment precluding accurate neurocognitive assessment.\n* history of heparin resistance.\n* chronic use of hypnotics (\\>3 times weekly for \\>4 weeks), mood stabilizing drugs (lithium, Na valoprate, anticonvulsants) or melatonin.\n* pre-operative pacing.\n* recent nasal surgery (\\\u003C3 months), prior maxillofacial trauma with nasal deformity, nasal polyposis or severe allergic rhinitis.\n* severe obstructive sleep apnea (apnea hypopnea index \\>30), central sleep apnea or obesity-hypoventilation syndrome, and planned postoperative non-invasive ventilation.\n* Chronic acholic population Alcohol Use Disorders Identification Test (AUDIT) score ≥8 for men or ≥7 for women","60 Years",{"count":234,"type":22},150,[236],"EARLY_PHASE1","On pump coronary revascularization is a very common leading cause for post-operative cognitive dysfunction regarding patient age grouping and diffuse systemic inflammatory response induced by bypass machine . Many factors are incriminated as pre-operative sleep disturbance, previous history of neurocognitive dysfunction. The accumulating evidence refers to an incidence between 20-40% with majority among geriatric population. The primary pathology is still elusive and many trials are under evaluation. Neuro-inflammation, hypo perfusion, fat emboli and reperfusion injury are among the most postulative aetiologias. The corner stone in the pathology of postoperative cognitive dysfunction is abnormal sleep rhythm. Intra-nasal insulin can provide neuroprotection via providing insulin growth factor and obtund neuronal apoptosis , while dexmedetomidine can antagonize neural-degeneration via regulation of systematic inflammatory cytokines including interleukin 1β, tumor necrosis factor-α, and NF-κB, inhibiting the expressions of Toll-like receptor , and through α2 adrenoceptor-mediated anti-inflammatory pathways",[239],"Post Operative Cognitive Dysfunction","2026-04-28",{"date":242,"type":41},"2026-05-04",{"date":244,"type":41},"2024-12-27",{"date":246,"type":22},"2026-05-15",{"name":47,"class":48},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":60,"phases":256,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":49},"100636345","phase-2-alpha-lipoic-acid-in-mitigating-cisplatin-induced-nephrotoxicity-100636345","NCT07564479","Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity","Evaluation of Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity in Oncology Patients","Inclusion Criteria:\n\n* Age ≥ 18 years. Histologically confirmed solid malignancy. Planned treatment with cisplatin starting from a dose of 60 mg\u002Fm2 per cycle (21-28 days each or fractionated).\n\nEastern Cooperative Oncology Group (ECOG) performance status 0-2. Baseline serum creatinine within normal range or estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73 m2.\n\nAbility to provide informed consent.\n\nExclusion Criteria:\n\n* Pre existing renal impairment (eGFR \\\u003C 60〖\" mL\u002Fmin\u002F1.73 m\" 〗\\^2or serum creatinine \\> 1.5 × upper limit of normal).\n\nConcomitant use of known nephrotoxic drugs that cannot be stopped (e.g., aminoglycosides, amphotericin B, high dose NSAIDs).\n\nUncontrolled hypertension, decompensated heart failure, or severe hepatic impairment.\n\nKnown allergy or intolerance to ALA. Pregnancy or lactation. Participation in another interventional clinical trial.",{"count":151,"type":22},[257],"PHASE2","To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes",[260,261],"Cisplatin Nephrotoxicity","Nephrotoxicity",[263,261,264,265],"Cisplatin","ALA","Alpha-Lipoic Acid","2026-04-26",{"date":242,"type":41},{"date":269,"type":41},"2026-03-10",{"date":271,"type":22},"2027-06",{"name":47,"class":48},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":125,"minAge":18,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":60,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":49},"100579417","early-phase-1-comparison-of-nebulized-neostigmineatropine-versus-lignocaine-in-treating-acute-post-dural-puncture-headache-following-subarachnoid-block-in-parturient-undergoing-elective-cesarean-section-a-randomized-clinical-trial-100579417","NCT06824025","Comparison of Nebulized Neostigmine\u002FAtropine Versus Lignocaine in Treating Acute Post-dural Puncture Headache Following Subarachnoid Block in Parturient Undergoing Elective Cesarean Section. A Randomized, Clinical Trial.","Inclusion Criteria:\n\n* 18-35 years old parturient with post partum headache after elective CS under spinal anesthesia with visual analog score (VAS) ≥ 4 \\[14\\] and Lybecker classification score ≥ 2\n\nExclusion Criteria:\n\n* Pregnancy induced hypertension\n* Emergency C.S\n* Asthmatic candidates\n* Previous history of migraine or trigeminal neuralgia\n* History of bronchial asthma\n* Post partum hemorrhage\n* Need for GA , failed spinal anesthesia\n* Patient refusal","35 Years",{"count":281,"type":22},111,[236],"Post-dural puncture headache (PDPH) is a common and debilitating complication of spinal anesthesia in pregnant patients undergoing cesarean sections, with an incidence ranging from 0.5% to 2% (1). The International Headache Society (IHS) defines PDPH as a headache occurring within 4 days of a lumbar puncture, caused by cerebrospinal fluid (CSF) leakage through the dural puncture (2). Although the exact cause of PDPH is not fully understood, it is thought to occur due to cerebrospinal fluid loss through dural tears, which leads to tension on pain-sensitive intracranial structures and reflex, uncontrolled cerebral vasodilation leading to severe agonizing tension headache (3). Treatment options include proper hydration, maintaining a supine position, caffeine, paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs). Many adjuvants have been questioned for their therapeutic effectiveness in enhancing conservative medical treatments, with conflicting results (4). For example, sumatriptan, theophylline and dexmedetomidine have been extensively studied. Neostigmine has emerged as a promising pharmacological adjuvant for conservative management. Neostigmine increases the serum level of acetylcholine via inhibition of cholinesterase (5). This action mediates cerebral vasoconstriction via nicotinic receptors, thus antagonizing the unopposed vasodilatation occurred due to dural tear. Lidocaine, on the other hand, can mediate sphenopalatine ganglion block which is responsible for pain signals transmission from the face (6).",[285],"Post-Dural Puncture Headache","2026-04-25",{"date":288,"type":41},"2026-04-30",{"date":290,"type":41},"2025-02-20",{"date":292,"type":22},"2027-01-05",{"name":47,"class":48},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":4},"100635865","carotid-intima-media-thickness-in-dialysis-patients-and-traditional-risk-factors-100635865","NCT07558239","Carotid Intima-media Thickness in Dialysis Patients and Traditional Risk Factors","Association of Traditional Cardiovascular and Dialysis-Specific Risk Factors With Carotid Intima-Media Thickness in Hemodialysis Patients: A Cross-Sectional Study\"","Inclusion Criteria:\n\n* 1\\. Age 18 or older. 2. Patients with sepsis without AKI at the time of admission.\n\nExclusion Criteria:\n\n* o Active malignancy\n\n  * Acute infections\n  * Recent cardiovascular events (\\\u003C3 months)\n  * Poor echocardiographic window for CIMT measurement",{"count":59,"type":22},"* Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients.\n* Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis.\n* Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.",[304,305,306],"Dialysis Patients","Hypertension","Atherosclerosis",[308,309],"Renal dialysis","Carotid intima- media thickness","2026-04-23",{"date":288,"type":41},{"date":313,"type":22},"2026-04-24",{"date":73,"type":22},{"name":47,"class":48},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":125,"minAge":103,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":60,"phases":326,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":49},"100562799","early-phase-1-nebulized-dexmedetomidine-or-lidocaine-for-treatment-of-post-dural-puncture-headache-in-parturients-undergoing-elective-cesarean-section-under-spinal-anesthesia-100562799","NCT06607861","Nebulized Dexmedetomidine or Lidocaine for Treatment of Post Dural Puncture Headache in Parturients Undergoing Elective Cesarean Section Under Spinal Anesthesia","Nebulized Dexmedetomidine or Lidocaine for Treatment of Post Dural Puncture Headache in Parturients Undergoing Elective Cesarean Section Under Spinal Anesthesia: A Randomized Bicentric Study","Inclusion Criteria:\n\n* Post partum headache for parturient with elective CS under spinal anesthesia with visual analog score (VAS) ≥ 4 \\[14\\] and Lybecker classification score ≥ 2\n\nExclusion Criteria:\n\n* Emergency caesarean section.\n* Pregnancy induced hypertension\n* Contraindications for sub-arachinoid block ( coagulopathy, infection )\n* History of chronic headache, migraine, trigeminal neuralgia\n* Refusal to participate\n* History of cerebrovascular stroke\n* BMI\\> 35\n* Prior maxillofacial with nasal deformity, Recent nasal surgery (\\\u003C3 months) Nasal polyposis or severe allergic rhinitis\n* Severe OSA (AHI\\>30) , OBESITY HYPOVENTILATION SYNDROME, CENTRAL APNEA SYBDROME\n* History of obstructive sleep apnea.","40 Years",{"count":325,"type":22},114,[236],"Post-dural puncture headache (PDPH) is a well-recognized and potentially serious complication of subarachnoid block. While advancements in spinal needle design have reduced its incidence in recent years, PDPH still affects a notable percentage of post-partum patients undergoing spinal anaesthesia, with rates ranging from 0.5% to 2%. Factors such as female gender, pregnancy, young age, low body mass index, dilutional anemia, and the preference for neuraxial anaesthesia during caesarean section (CS) increase the vulnerability of obstetric patients to PDPH. Therefore, managing this complication is critically important in obstetric anaesthesia.\n\nThe exact cause of PDPH remains unclear, but there is substantial evidence suggesting that it stems from reduced cerebrospinal fluid (CSF) pressure due to continuous leakage through a dural tear, which exceeds the rate of CSF production. This imbalance can lead to PDPH, as even a modest loss of CSF volume (as little as 10%) can trigger traction on pain-sensitive intracranial structures when in an upright position, compounded by reflexive vasodilation.\n\nVarious treatment strategies have been proposed, typically including bed rest in a supine position, fluid therapy, analgesics, and medications such as sumatriptan and caffeine.\n\nDexmedetomidine (DEX) is a highly specific agonist of α2-adrenoreceptors known for inducing cooperative sedation, anxiolysis, and analgesia while minimizing respiratory depression. Additionally, it has been shown to mitigate the stress and inflammatory response triggered by surgical and anaesthetic procedures. Activation of α2-receptors in the substantia gelatinosa of the dorsal horn suppresses the firing of nociceptive neurons and inhibits the release of substance P. Furthermore, stimulation of these receptors in the locus coeruleus, a key modulator of nociceptive transmission, interrupts the transmission of pain signals, resulting in analgesia. Dexmedetomidine has been administered via intranasal and inhalational routes for various purposes, including premedication, sedation, and post-operative analgesia.\n\nLidocaine nebulized is a novel method used recently for PDPH. Intranasal lidocaine can offer sphenopalatine ganglion block which can facilitate acute pain reduction in PDPH.",[329],"Pain Score (VAS)","2026-04-22",{"date":310,"type":41},{"date":333,"type":41},"2024-06-01",{"date":335,"type":22},"2026-06-06",{"name":47,"class":48},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":125,"minAge":18,"maxAge":104,"enrollmentInfo":343,"targetDuration":4,"studyType":60,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100633360","vacuum-sealing-drainage-vsd-in-promoting-wound-healing-and-reducing-complications-in-post-infected-obstetric-and-gynecological-surgical-sites-100633360","NCT07525674","Vacuum Sealing Drainage (VSD) in Promoting Wound Healing and Reducing Complications in Post-Infected Obstetric and Gynecological Surgical Sites","Inclusion Criteria:\n\n* Diagnosis of a surgical site infection (SSI) following an obstetric or gynecological surgical procedure (e.g., Cesarean section, hysterectomy, myomectomy, salpingo-oophorectomy).\n* Wound classification as superficial incisional SSI, deep incisional SSI, or organ\u002Fspace SSI (if accessible for VSD application).\n* Willingness and ability to provide informed consent.\n* Wound requiring secondary intention healing or delayed primary closure after debridement\n\nExclusion Criteria:\n\n* Patients with necrotic tissue.\n* Presence of exposed blood vessels, organs, or anastomotic sites where VSD is contraindicated.\n* Untreated coagulopathy or active bleeding diathesis.\n* Allergy to VSD components or dressing materials.\n* Patients with significant immunosuppression (e.g., uncontrolled HIV, organ transplant recipients on high-dose immunosuppressants).\n* Patients with malignant wounds.\n* Patients who decline participation.\n* Patients requiring immediate primary wound closure without debridement.\n* Patients with a known history of severe psychiatric illness affecting compliance.",{"count":344,"type":22},30,[62],"This study aims to evaluate the efficacy of VSD in promoting wound healing and reducing complications, such as re-infection, prolonged hospitalization, and need for further surgical interventions, in obstetric and gynecological patients who have developed surgical site infections following their primary procedures. The investigators hypothesize that VSD will lead to faster wound healing, fewer complications, and improved patient outcomes compared to conventional wound care in this specific patient population.",[348],"Wound Heal","2026-04-13",{"date":351,"type":41},"2026-04-16",{"date":353,"type":22},"2026-04-20",{"date":355,"type":22},"2027-04-20",{"name":47,"class":48},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":125,"minAge":18,"maxAge":126,"enrollmentInfo":363,"targetDuration":4,"studyType":60,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100633661","laparoscopic-umbilico-uterine-trunk-clipping-approach-in-the-management-of-enhanced-myometrial-vascularity-100633661","NCT07529587","Laparoscopic Umbilico-uterine Trunk Clipping Approach in the Management of Enhanced Myometrial Vascularity","Inclusion Criteria:\n\n1. Confirmed diagnosis of Enhanced Myometrial Vascularity.\n2. Presence of clinical symptoms related to Enhanced Myometrial Vascularity: Such as menorrhagia affecting quality of life, or abnormal uterine bleeding (AUB) unresponsive to initial medical treatments.\n3. Women of reproductive age (18-45 years).\n4. Willingness to undergo surgical treatment: Participants must be willing to undergo one of the two surgical procedures under investigation (laparoscopic umbilico-uterine trunk clipping or Mirena Intrauterine Device Insertion).\n5. Written informed consent: Participants must be able to understand the study information and provide written informed consent to participate.\n6. Adequate general health to undergo anesthesia and laparoscopic surgery: This will be assessed by the responsible physician\n\nExclusion Criteria:\n\n1. Presence of other known causes of menorrhagia or abnormal uterine bleeding: Such as large uterine fibroids (\\> 3 cm in diameter, or with a location causing distortion of the uterine cavity), large endometrial polyps, untreated endometrial hyperplasia, or known bleeding disorders.\n2. History of extensive prior pelvic surgery: That may increase the difficulty or risks of laparoscopic surgery or significantly affect uterine blood supply.\n3. Current pregnancy or suspicion of pregnancy: Pregnancy testing will be performed before enrollment.\n4. Current breastfeeding.\n5. Presence of contraindications to general anesthesia or laparoscopic surgery: This will be assessed by the anesthesiologist.\n6. Severe, unstable systemic diseases: Such as uncontrolled cardiovascular disease, pulmonary disease, renal disease, or liver disease.\n7. Receiving hormonal therapy that affects the menstrual cycle or uterine blood flow.\n8. Participation in another clinical trial that could interfere with the outcomes of this study.\n9. Inability to comply with study procedures or follow-up.\n10. Any other condition that the principal investigator deems would compromise the safety of the participant or affect the study outcomes.",{"count":364,"type":22},56,[62],"This study aims to address this knowledge gap by conducting a randomized active-controlled trial comparing laparoscopic umbilico-uterine trunk clipping with Mirena Intrauterine Device Insertion (an active treatment method chosen and justified based on current clinical practice) in reducing monthly menstrual blood loss in women with enhanced myometrial vascularity. By providing reliable data on clinical efficacy and patient-related outcomes, this study can contribute to guiding clinical decision-making and improving the care of women with this condition.",[368],"Enhanced Myometrial Vascularity","2026-04-10",{"date":371,"type":41},"2026-04-14",{"date":369,"type":22},{"date":374,"type":22},"2027-04-10",{"name":47,"class":48},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":60,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":49},"100633020","noninvasive-technique-and-high-flow-nasal-oxygen-in-respiratory-failure-100633020","NCT07521254","Noninvasive Technique and High Flow Nasal Oxygen in Respiratory Failure","Different Modalities of Combined Noninvasive Ventilation With High Flow Nasal Oxygen Versus Noninvasive Ventilation Alone in Acute Respiratory Failure","Inclusion Criteria:\n\n* Age ≥18 year of both sexes. • Diagnosed with Acute Respiratory Failure (ARF) defined as the combination of a PaO2\u002FFiO2 ratio \\\u003C 300 after 15 minutes of conventional oxygen delivered through a face mask, with a FiO2 at least of 50% and respiratory rate \\> 30 breaths\u002Fmin.\n\nExclusion Criteria:\n\n* Chronic respiratory disease\n\n  * Cardiogenic pulmonary edema\n  * Life-threatening arrythmias\n  * Hemodynamic instability requiring vasopressors\n  * Facial abnormalities preventing NIV or HFNC application\n  * Glasgow coma score of ≤ 12 points (Teasdale et al. 1974)\n  * Agitated patients characterized by RASS score (Richmond Agitation Sedation Scale) ≥ +2\n  * Patients who needed immediate endotracheal intubation\n  * Pregnant patients",{"count":5,"type":22},[62],"After obtaining Institutional Ethical Committee approval of Faculty of Medicine, Minia University and written informed consent from patients or first- degree relatives, this prospective randomized non-blind comparative study will be conducted in adult intensive care unit (ICU) of Anesthesia, Intensive Care and Pain management department Minia university hospital over a period from September 2025 to April 2026. This study is designed to compare the effectiveness of two protocols of sequential use of High Flow Nasal Cannula (HFNC) and noninvasive ventilation (NIV) versus NIV alone in patients with Acute Respiratory failure (ARF) admitted to the intensive care unit (ICU). The study will include 75 patients of both sexes, classified as ASA class Ⅰ-ⅠⅠⅠ, divided into three groups with 25 patients in each group.",[387],"Respiratory Failure",[389,390,391,392],"Noninvasive technique in treatment of respiratory failure","Noninvasive ventilation","Respiratory failure","High flow nasal oxygen","2026-04-07",{"date":395,"type":41},"2026-04-09",{"date":397,"type":41},"2025-06-01",{"date":399,"type":22},"2026-05",{"name":47,"class":48},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":125,"minAge":18,"maxAge":126,"enrollmentInfo":407,"targetDuration":4,"studyType":60,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100633361","temporary-uterine-tourniquet-application-versus-local-myometrial-epinephrine-injection-during-laparoscopic-myomectomy-100633361","NCT07525687","Temporary Uterine Tourniquet Application Versus Local Myometrial Epinephrine Injection During Laparoscopic Myomectomy","Inclusion Criteria:\n\n* Female patients aged 18-45 years.\n* Diagnosed with symptomatic uterine leiomyomas requiring laparoscopic myomectomy.\n* Presence of at least one myoma with a diameter ≥3 cm and ≤10 cm.\n* Patients with up to 3 myomas (to standardize surgical complexity).\n* Preoperative hemoglobin level ≥10 g\u002FdL.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with more than 3 myomas or any myoma larger than 10 cm.\n* Patients with suspected uterine malignancy (e.g., leiomyosarcoma).\n* Patients with known bleeding disorders or on anticoagulant therapy that cannot be safely discontinued.\n* Patients with significant cardiovascular disease, uncontrolled hypertension, or arrhythmias (relative contraindications for epinephrine).\n* Patients with active pelvic infection.\n* Patients with previous extensive uterine surgery (e.g., multiple prior myomectomies or extensive uterine reconstruction) that may compromise uterine integrity.\n* Patients undergoing concurrent major gynecological procedures that might significantly affect blood loss (e.g., hysterectomy, extensive adhesiolysis).\n* Patients with known allergy to epinephrine.\n* Patients unwilling or unable to comply with follow-up protocols.",{"count":408,"type":22},37,[62],"While both local vasoconstrictors and tourniquet application are recognized methods for blood loss control, there is a paucity of head-to-head randomized controlled trials directly comparing these two distinct approaches in laparoscopic myomectomy. Existing data often compare these methods to no intervention or to other less common techniques. A direct comparison is essential to determine which method offers superior hemostasis with an acceptable safety profile in the laparoscopic setting. This study aims to address this gap in the literature.",[412],"Laparoscopic Myomectomy","2026-04-06",{"date":349,"type":41},{"date":353,"type":22},{"date":417,"type":22},"2027-01-20",{"name":47,"class":48},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":426,"targetDuration":4,"studyType":60,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":49},"100574191","phase-2-reinforced-pancreaticojejunostomy-with-or-without-glubran2-100574191","NCT06756074","Reinforced Pancreaticojejunostomy With or Without glubran2","Impact of Reinforced Pancreaticojejunostomy With or Without Tissue Adhesive Glue Modified Cyanoacrylate (Glubran 2) Following Pancreaticoduodenectomy, Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* All the patients undergoing pancreaticoduodenectomy for cancer\n* Patients able to give their informed consent\n\nExclusion Criteria:\n\n* Unfit patients for surgery due to severe medical illness.\n* Inoperable patients by imaging studies, irresectable tumors after laparotomy or diagnostic laparoscopy.\n* Presence of distant metastasis .\n* Patients refused to participate in the study.",{"count":59,"type":22},[257],"Pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. To reduce pancreatic fistula, many authors recommend different techniques in pancreatojejunostomy. The purpose of this study is to determine which is the best method in preventing pancreatic fistula by enforce pancreaticojejunostomy with tissue glue .",[67,65,70,430],"Pancreatic Ductal Adenocarcinoma","2026-03-13",{"date":433,"type":41},"2026-03-16",{"date":435,"type":41},"2025-01-15",{"date":246,"type":22},{"name":47,"class":48},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":201,"sex":17,"minAge":18,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":447,"conditions":448,"keywords":453,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100626410","kinesiophobia-in-rheumatoid-arthritis-associations-with-functional-disability-disease-activity-and-related-clinical-factors-100626410","NCT07435272","Kinesiophobia in Rheumatoid Arthritis: Associations With Functional Disability, Disease Activity, and Related Clinical Factors","Inclusion Criteria:\n\n* Age: adult population with RA (18-69)\n* Disease duration ≥ 6 months\n\nExclusion Criteria:\n\n1. Juvenile cases\n2. Other rheumatic diseases (SLE, AS, 1ry OA, etc.)\n3. Trauma\n4. Comorbidities that affect mobility, e.g., UMNL (including stroke), parkinsonism, multiple sclerosis, cerebral palsy, dementia, peripheral neuropathy, chronic pain conditions, etc.\n5. Previous history of psychiatric illness before onset of RA (anxiety, depression, etc.)\n6. Pregnancy and lactation","69 Years",{"count":446,"type":22},400,"Objectives: Impairment of physical function is a core feature of RA, particularly in patients with high disease activity where pain and inflammation directly limit movement. but, Reduced mobility in RA is not exclusively driven by inflammatory pathology. There are non-inflammatory factors, including kinesiophobia, fatigue, depression, and anxiety, may significantly contribute to functional limitation and may initiate a self-perpetuating cycle in which movement avoidance leads to physical deconditioning, muscle weakness, and progressive functional decline. The aim of this study is to examine the relationship between kinesiophobia and functional outcomes in patients with rheumatoid arthritis, and to investigate its associations with disease activity, pain, fatigue, depressive symptoms, anxiety, and sarcopenia, with a focus on factors relevant to functional assessment and rehabilitation.\n\nPatients and Methods\n\nA case - control study will be conducted on Two hundred adult patients previously diagnosed with RA according to ACR\u002FEULAR 2010 criteria for RA and 200 apparently healthy volunteers with age and sex matching will be involved in the study. The study will be conducted in Rheumatology department, Minia university Hospital, Egypt. All patients will be subjected to history taking, clinical examination, and assessment of the following parameters:\n\n1. Kinesiophobia: using the Arabic version of TSK-17\n2. Disease activity: using DAS 28\n3. pain severity using the Visual Analogue Scale (VAS)\n4. Fatigue: using the Arabic version of the Fatigue Severity Scale (FSS)\n5. Depression: using the Arabic version of the BDI-2\n6. Anxiety: using the Arabic version of the BAI\n7. sarcopenia using the Arabic version of the SARC-F questionnaire\n8. Functional disability: using the Arabic version of the HAQ-DI\n9. Physical activity:using IPAQ-SF",[449,450,451,452],"Kinesiophobia (Fear of Movement)","Rhematoid Arthritis","Rheumatoid Arthritis (RA)","Rheumatoid",[454,455,456,457,458,459,460,461,462,463],"Kinesiophobia","Fear of Movement","Rheumatoid Arthritis","Functional Disability","Disease Activity","Pain","Fatigue","Anxiety","Depression","sarcopenia","2026-02-27",{"date":466,"type":41},"2026-03-03",{"date":468,"type":22},"2026-03-01",{"date":470,"type":22},"2026-10-01",{"name":47,"class":48},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":480,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":60,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":49},"100625012","cgf-partial-pulpotomy-versus-endodontic-treatment-100625012","NCT07417098","CGF Partial Pulpotomy Versus Endodontic Treatment","Partial Pulpotomy Usung CGF Versus Endodontic Treatment in Treating Irreversibly Inflamed Mature Peramnent Molars","CGF Vs Endo","Inclusion Criteria:\n\n* Patient-based criteria: Class ASA I or II cooperative adolescents of 11 - 17 years. Based on a 10 cm modified visual analog scale (VAS), only patients who reported a preoperative pain intensity score of ≥ 7, indicative of severe pain were included.\n\nTooth-based criteria: Presence of occlusal extremely deep carious lesion with pulp exposure of mandibular first permanent molars with closed apices (i.e. class V according to Cvek's stages of root development) with sound contralateral molars to provide a reference for biomarker quantification and pulp sensibility tests. Only teeth diagnosed with symptomatic irreversible pulpitis (SIP) were included. To validate the diagnosis of SIP, the teeth with the teeth diagnosed with symptomatic irreversible pulpitis (SIP) were included. To validate the diagnosis of SIP, the teeth with the following criteria were exclusively included:\n\n1. History of sharp, spontaneous, and lingering pain that was precipitated by thermal provocation and lasted mostly for ≥ 30 seconds.\n2. Early prolonged, intense, and lingering response to cold thermal stimulus and positive response electric pulp test (EPT) at low thresholds.\n3. Normal color and appearance of the tooth surrounding gingival tissues with no evidence of gingival inflammation, swelling, abnormal tooth mobility, or sinus tract or fistula formation upon visual and palpation inspections.\n4. Preoperative periapical radiograph with evidence of caries penetrating the entire thickness of the dentin with no isolating radiopaque zone separating the lesion from the pulp indicating extremely deep caries.\n5. Normal radiographic findings in terms of intact periodontal membrane space\n\nExclusion Criteria:\n\nPatient-based criteria: Patients with a positive history of the following conditions were excluded:\n\n1. Emotional or behavioral problems and those receiving antidepressant drugs.\n2. Under treatment with antibacterial or anti-inflammatory medicaments for the last four weeks (Akbal Dincer et al., 2020).\n3. Localized or generalized gingivitis and\u002For periodontitis with loss of epithelial attachment ≥ 3mm upon probing.\n4. Poor oral hygiene with dense accumulation of calculus or dental plaque.\n5. Systemic conditions such as diabetes, bleeding, immunological disorders.\n\nTooth-based criteria:\n\n1. Teeth with abnormal structure or developmental anomalies.\n2. Persistent hemorrhage from the root canal orifices lasting longer than 10 minutes.\n3. Loss of coronal structure beyond restorability","11 Years","17 Years",{"count":483,"type":22},60,[62],"partial pulpotomy of mature molars with irrevesible pulptits using CGF in adolescents",[487],"Irreversible Pulpitis",[489],"partial pulpotomy , CGF","2026-02-10",{"date":492,"type":41},"2026-02-18",{"date":494,"type":22},"2026-01-20",{"date":496,"type":22},"2028-01-25",{"name":47,"class":48},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":506,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":60,"phases":508,"briefSummary":509,"conditions":510,"keywords":513,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":49},"100625008","possible-beneficial-effects-of-combined-fluoxetine-and-occlusion-therapy-in-improving-and-maintaining-vision-in-amblyopia-using-optical-coherence-tomography-angiography-octa-and-visual-evoked-potential-vep-the-aim-of-the-study-is-to-evaluate-possible-beneficial-effects-for-different-age-groups-100625008","NCT07417046","Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopia Using Optical Coherence Tomography Angiography (OCTA) And Visual Evoked Potential (VEP). The Aim Of The Study Is To Evaluate Possible Beneficial Effects For Different Age Groups.","Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopia Using Optical Coherence Tomography Angiography (OCTA) And Visual Evoked Potential (VEP)","VA; OCTA; VEP;","Inclusion Criteria:\n\n* Patients with unilateral amblyopia \\> 10 years old.\n\nExclusion Criteria:\n\n* Ocular pathology: media opacity, uveitis, glaucoma, retinal or optic nerve diseases, and history of ocular trauma.\n\n  * Poor fixation.\n  * Lack of cooperation.\n  * Any psychological disorder.","10 Years",{"count":151,"type":22},[62],"Amblyopia is described as a limitation of the visual function of one or both eyes with no pathological cause, with a prevalence of about 1-5% of the total world population. This disorder is caused by early abnormal visual experience with a functional imbalance between the two eyes owing to anisometropia, strabismus, congenital cataract and ptosis, resulting in a dramatic loss of visual acuity (VA) in an apparently healthy eye.\n\nClinically, amblyopia can be defined as the presence in one or both eyes of a VA of 6\u002F12 or worse, with one or more lines of difference in VA between eyes in unilateral amblyopia which cannot be improved by refractive correction. This condition is an alteration of the visual cortex function which is due to suppression and deprivation of one eye leading to unilateral visual deterioration.\n\nOptical coherence tomography (OCT) is a noninvasive technique that can reveal morphology of the retinal layers in vivo. OCT determines structural changes in the macula that may be correlated with measures of subjective visual function such as visual acuity and visual field. OCT angiography (OCTA) can provide vascular system visualization of the posterior segment in amblyopic eyes.\n\nVisual evoked potentials (VEPs) are a non-invasive technique routinely used in clinical and preclinical practice. VEPs allow to quantify the functional integrity of the visual system from the retina via the optic nerves, optic tracts, to the thalamus, and form projections to the visual cortices.\n\nIn strabismic and anisometropic amblyopia, VEP responses are reduced. VEP may be used as an alternative objective method for diagnosis and monitoring of amblyopia.\n\nPassive treatments such as occlusion, optical and\u002For pharmacological penalization, and Bangerter foils have been demonstrated to be potentially useful treatments for amblyopia. Researches are being done on new pharmacological options to improve and maintain VA after occlusion treatment in amblyopia.\n\nAdults with amblyopia cannot be treated because their brains do not have enough plasticity. However, results obtained both in clinical trials and in animal models have challenged this traditional view, unmasking a previously unsuspected potential for promoting recovery after the end of the critical period for visual cortex plasticity. These studies point toward the intracortical inhibitory transmission as a crucial brake for therapeutic rehabilitation and recovery from amblyopia in the adult brain.\n\nSelective serotonin reuptake inhibitors (SSRIs) increase serotonin activity in the brain. While they are mostly known for their antidepressant properties, they have been shown to improve visual functions in amblyopia and impact cognitive functions ranging from attention to motivation and sensitivity to reward.",[511,512],"Amblyopia","VEP",[514,512,515,511],"Flouxetine","OCTA",{"date":492,"type":41},{"date":518,"type":41},"2024-12-01",{"date":520,"type":22},"2026-04-01",{"name":47,"class":48},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":529,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":537,"leadSponsor":539,"locationsCount":4},"100623146","postoperative-cognitive-dysfunction-in-elderly-and-its-relation-with-sleep-disorders-and-melanin-concentrating-hormone-100623146","NCT07392840","Postoperative Cognitive Dysfunction in Elderly and it's Relation With Sleep Disorders and Melanin Concentrating Hormone","Postoperative Delayed Neurocognitive Recovery in Elderly Patients Undergoing Spinal Anesthesia: Assessment of Its Prevalence and Correlation With Preoperative Sleep Disorders and Melanin Concentrating Hormone.","Inclusion Criteria:\n\n* Patients of both genders ageing 65 years or above.\n* ASA grade I to III.\n* Undergo elective lower limb surgery under spinal anesthesia\n* Agree to collect one's own CSF and blood samples\n\nExclusion Criteria:\n\n* Past history of depression,anxiety,delirium and schizophrenia .\n* Past history of drug dependence.\n* Past history of dementia,including Alzheimer disease(AD).\n* Preoperative Montreal Cognitive Assessment (MoCA) score \\\u003C26.\n* Inability to understand or cooperate with the evaluation scale or questionnaire.\n* Refuse collecting one's own CSF and blood samples.","65 Years",{"count":151,"type":22},"The aim of this study is to explore the relationship between preoperative sleep disorders, melanin-concentrating hormone (MCH), and delayed neurocognitive recovery early after surgery in older adult patients undergoing spinal anesthesia.",[533],"Postoperative Cognitive Dysfunction","2026-02-06",{"date":490,"type":41},{"date":160,"type":22},{"date":538,"type":22},"2027-04-01",{"name":47,"class":48},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":60,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":49},"100623255","intrastromal-moxifloxacin-as-an-adjunctive-therapy-in-recalcitrant-bacterial-keratitis-100623255","NCT07394257","Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Clinical diagnosis of bacterial keratitis confirmed by corneal scraping and microbiology\n  * Recalcitrant keratitis defined as no significant clinical improvement after 48-72 hours of intensive topical antibiotic therapy\n  * Ability to provide written informed consent\n\nExclusion Criteria\n\n* Fungal, viral, or acanthamoeba keratitis\n* Corneal perforation or impending perforation\n* Known hypersensitivity to fluoroquinolones\n* Pregnancy or lactation\n* Immunocompromised state or current systemic immunosuppressive therapy\n* Previous intrastromal or intracameral antibiotic injection for the same episode",{"count":483,"type":22},[62],"Bacterial keratitis is a potentially sight-threatening corneal infection that is commonly treated with intensive topical antibiotics. Despite appropriate therapy, some cases show inadequate clinical response, particularly when the infection involves the deep corneal stroma. Limited penetration of topical antibiotics into deeper corneal layers may contribute to treatment failure in these recalcitrant cases.\n\nIntrastromal antibiotic injection is a targeted drug-delivery approach that allows high local antimicrobial concentrations directly at the site of infection. Moxifloxacin is a broad-spectrum fluoroquinolone with proven efficacy in bacterial keratitis and favorable corneal tissue penetration. However, evidence regarding the clinical benefit and safety of intrastromal moxifloxacin as an adjunctive treatment remains limited.\n\nThis randomized controlled trial aims to evaluate the efficacy and safety of intrastromal moxifloxacin injection as an adjunct to standard topical moxifloxacin therapy compared with topical therapy alone in patients with recalcitrant bacterial keratitis. The primary outcome is time to complete clinical resolution of infection. Secondary outcomes include visual acuity improvement, ulcer healing rate, need for additional interventions, and treatment-related complications.",[550,551,552],"Bacterial Keratitis","Recalcitrant Infectious Keratitis","Corneal Ulcer",{"date":534,"type":41},{"date":555,"type":41},"2025-10-01",{"date":520,"type":22},{"name":47,"class":48},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":565,"targetDuration":4,"studyType":60,"phases":566,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":49},"100622701","comparison-of-laparoscopic-nissen-fundoplication-and-hill-snow-repair-for-hiatus-hernia-with-endoscopic-evaluation-100622701","NCT07387042","Comparison of Laparoscopic Nissen Fundoplication and Hill-Snow Repair for Hiatus Hernia With Endoscopic Evaluation","Comparison of Laparoscopic Nissen Fundoplication and Hill-Snow Repair for Hiatus Hernia With Endoscopic Evaluation: Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged less than 18 years including both sexes with a confirmed diagnosis of congenital hiatus hernia\n* Diagnosis of hiatus hernia refractory to maximal medical therapy (PPI for ≥12 weeks) AND\u002FOR presence of complications (e.g., erosive esophagitis, Barrett's esophagus, recurrent aspiration pneumonia, failure to thrive)\n* Objective evidence of pathological GERD on upper endoscopy e.g: erosive esophagitis, Barrett's esophagus.\n\nExclusion Criteria:\n\n* Previous esophageal or gastric surgery\n* Contraindications to laparoscopy e.g: cardiopulmonary decompensated cases.",{"count":203,"type":22},[62],"The goal of this clinical trial is to compare the clinical efficacy and safety of laparoscopic Nissen fundoplication (LNF) versus laparoscopic Hill-Snow repair (LHS) in the management of patients with congenital hiatus hernia, to evaluate the role of upper gastrointestinal endoscopy in the preoperative diagnosis and planning \\& to determine the utility of intraoperative endoscopy in guiding the surgical repair and ensuring its technical adequacy.\n\nmain questions are:\n\n* which one of these techniques is safer with higher clinical efficacy represented by relief of GERD symptoms ?\n* does upper GI endoscopy have a role in preoperative stage regarding diagnosis of condition and planning of treatment ?\n* does upper GI endoscopy have a role in intraoperative stage regarding guiding the surgical repair and ensuring its adequacy ?\n\nall participants will be randomly assigned in one of two groups:\n\n* one group undergoing Laparoscopic Nissen Fundoplication\n* the other group undergoing Laparoscopic Hill-Snow repair\n\neach participsant will have preopertive, intraoperative and postoperative upper GI endoscopy to assess objectively clinical efficacy of both techniques and to define the integral role of endoscopy in all three perioperative stages",[569],"Hiatal Hernia With Gastroesophageal Reflux Disease",[571,572,573,574],"Hiatus Hernia","Nissen Fundoplication","Hill-Snow repair","Endoscopy","2026-01-28",{"date":577,"type":41},"2026-02-04",{"date":579,"type":22},"2026-03",{"date":581,"type":22},"2027-10",{"name":47,"class":48},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":201,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":590,"targetDuration":4,"studyType":60,"phases":591,"briefSummary":592,"conditions":593,"keywords":597,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":603,"locationsCount":4},"100622467","comparison-between-external-oblique-intercostal-plane-block-and-rectus-sheath-block-combined-with-transversus-abdominis-plane-block-100622467","NCT07384000","Comparison Between External Oblique Intercostal Plane Block and Rectus Sheath Block Combined With Transversus Abdominis Plane Block","The Efficacy of Single Puncture Technique of Rectus Sheath Block Combined With Transversus Abdominis Plane Block Versus External Oblique Intercostal Plane Block for Pain Control After Laparoscopic Cholecystectomy.","Inclusion Criteria:\n\n* Patients undergoing elective laparoscopic cholecystectomy\n* American Society of Anesthesiologists (ASA) 1-II\n* aged 18-70 years\n* both genders will be included.\n* body mass index (BMI) ≤ 35 kg\u002Fm2.\n\nExclusion Criteria:\n\n* coagulation disorders\n* liver\u002Fkidney disease\n* History of abdominal surgery\n* infection in the block application area\n* chronic opioid use\n* local anesthetic (LA) allergy\n* Pregnancy",{"count":483,"type":22},[62],"Effective perioperative pain management remains a cornerstone in enhancing recovery and improving patient outcomes in laparoscopic cholecystectomy. This minimally invasive procedure, although less traumatic compared to open surgery, can still lead to significant postoperative pain, particularly in the early hours following the operation. Insufficient pain control may result in delayed mobilization, prolonged hospital stays, and increased opioid consumption, which are associated with adverse side effects and a heightened risk of complications . Regional anesthesia techniques have garnered significant attention for their ability to provide localized, opioid-sparing analgesia, thereby improving postoperative recovery profiles.External Oblique Intercostal Plane Block (EOIP) is a relatively new regional anesthesia technique targeting the intercostal nerves (T7-T11) as they traverse the plane between the external and internal oblique muscles. This block has demonstrated efficacy in controlling postoperative pain for upper abdominal surgeries, including laparoscopic cholecystectomy. By selectively anesthetizing the sensory branches of the thoracoabdominal nerves, the EOIP block provides localized analgesia with minimal motor blockade, making it an ideal choice for early mobilization (Ouchi et al., 2020).Recent advancements in ultrasound-guided techniques have improved the precision and safety of the EOIP block, allowing for consistent blockade of the targeted nerves. Clinical trials have highlighted its ability to reduce the pain significantly in the first 24 hours postoperatively, along with a marked decrease in the need for rescue analgesics. Tranrversus abdominis plane block (TAP) , first described in the early 2000s, has undergone several modifications to improve its efficacy in abdominal surgeries. The subcostal TAP block targets the anterior branches of the lower thoracic nerves (T6-T9) to provide analgesia to the upper abdominal wall. This technique is particularly suited for laparoscopic cholecystectomy, where the pain originates predominantly from the pari0etal peritoneum and abdominal wall incisions.The single puncture technique of Rectus sheath block (RSB) combined with transversus abdominis plane block (TAPB) represents a more streamlined approach to abdominal wall analgesia. ultrasonography (US) guidance for peripheral nerve blocks has become more and more popular. Transversus abdominis plane block (TAPB) and US-guided rectus sheath block (RSB) have been utilized in abdominal surgeries and have shown strong analgesic effects. Prior researches has demonstrated that in abdominal surgery, US-guided (TAPB) in conjunction with (RSB) had superior analgesic effects than either (TAPB) or (RSB) alone. Currently, multipoint nerve block procedures are generally applied in clinical practice, but they are difficult and can increase the patient's suffering. A novel method is proposed based on the neuromuscular anatomy and the location of the incisiopn in laparoscopic upper abdominal surgery: US-guided transverse abdominis plane and rectus sheath block one-puncture .",[594,595,596],"Pain Management","Anesthesia , Analgesia","Nerve Block",[587],"2026-01-26",{"date":600,"type":41},"2026-02-03",{"date":494,"type":22},{"date":520,"type":22},{"name":47,"class":48},""]